Application Development for PXB Mice and Establishment of Intellectual Property Rights

「The company positions nucleic acid therapeutics and gene therapy in the safety field, and MASLD (metabolic dysfunction-associated steatotic liver disease) and lipid metabolism in the pharmacology and pharmacodynamics field, as important areas in new markets. It will work on application development and new product development for PXB mice and PXB-cells. The company has obtained basic patents for its core technology, PXB mice, in major regions including Japan and the United States, and will continue to focus on securing rights to intellectual property newly developed through in-house and joint research.」

「As new drug-discovery modalities emerge, use of PXB mice in the development of nucleic acid medicines, gene therapies and other products has increased, and inquiries from new customers have also increased as their usefulness has become more widely recognized.」

「In this environment, the Group is strengthening research and development into new devices and technologies, including Microphysiological Systems (MPS; biomimetic systems), which are being developed worldwide as in vitro evaluation methods. At the same time, through USC (University of Southern California), its joint research partner, the Group will identify trends in the United States, the primary arena for competition in pharmaceutical development, and seek to develop products aligned with market needs.」

「Demand for PXB mice is shifting from the hepatitis field to the biopharmaceutical field, with usage increasing in the development of nucleic acid therapeutics, gene therapy and other products.」

「In fields such as safety testing, PXB mice are gaining recognition as useful tools in pharmaceutical development involving nucleic acid therapeutics and gene therapy.」

「Demand for PXB mice in nucleic acid therapeutics is also stable.」

「The company is also developing models for applications in new areas, including nonalcoholic steatohepatitis and lipid metabolism, in the pharmacology and pharmacodynamics field.」

「To increase sales further, we will develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs.」

「To increase sales further, we will develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs.」

「To increase sales further, we will develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs.」

「In addition to the pharmacodynamic evaluation of anti-hepatitis B virus drugs, an area in which its PXB mice have a long track record, the company is seeing increased use in biopharmaceutical fields such as nucleic acid therapeutics.」

「To increase sales further, we will develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs.」

「The company will pursue new customer acquisition and expand applications for PXB mice and PXB-cells through consortium activities and business partnerships with CROs.」

「The company will pursue new customer acquisition and expand applications for PXB mice and PXB-cells through consortium activities and business partnerships with CROs.」

「The company is also developing models for applications in new areas, including nonalcoholic steatohepatitis and lipid metabolism, in the pharmacology and pharmacodynamics field.」

「In safety-related fields, which the Group positions as growth areas because they can target many new drugs, orders related to nucleic acid drugs in overseas markets, where the Group is pursuing market development, grew substantially, and orders and revenue exceeded the prior-year period.」

「Orders related to nucleic acid pharmaceuticals grew in overseas markets, and orders and net sales exceeded the levels recorded in the same period of the previous year.」

「In terms of earnings, the company posted an operating loss because substantial upfront costs were incurred at KMT Hepatech, Inc., a subsidiary investing in facilities as an overseas production base for PXB mice, and research and development expenses increased substantially following the launch of joint research with the University of Southern California to create new disease-model mice.」

「Orders in the nucleic acid therapeutics field, which is attracting attention as a next-generation pharmaceutical field, are increasing.」

「Because the field requires a track record in the form of academic data to achieve broader adoption, the Group is conducting joint research with pharmaceutical companies, universities and research institutions in Japan and overseas on the usefulness of PXB mice in this field. Going forward, it will continue validating the usefulness of PXB mice, developing applications and new disease models, and working to raise awareness in the DMPK/Tox fields.」

「Research on PXB mice presented at academic conferences and in papers serves as promotion, and the company states that the results led to new orders. Domestic revenue exceeded the year-earlier level because research results presented at an academic conference led to new orders, although」

「Research on PXB mice presented at academic conferences and in papers serves as promotion to researchers at pharmaceutical companies and other organizations, raising awareness of PXB mice in the DMPK/Tox fields, which cover a broad range of testing areas. Domestic revenue exceeded the year-earlier level because research results presented at domestic academic conferences in the previous consolidated fiscal year led to orders, although」

「Research on PXB mice presented at academic conferences and in papers serves as promotion to researchers at pharmaceutical companies and other organizations, raising awareness of PXB mice in the DMPK/Tox fields, which cover a broad range of testing areas. Domestic revenue remained firm because research results presented at domestic academic conferences in the previous consolidated fiscal year led to orders, although overseas revenue got off to a weak start.」

「To realize the potential market for PXB mice, it is necessary to develop applications for their use as laboratory animals in the drug-discovery process. In particular, testing methods using PXB mice as new evaluation tools for drug metabolism and safety testing within nonclinical studies have strong prospects. The standalone added value of PXB mice is limited by their role as laboratory animals, but application development can make the high-margin business model sustainable. The research and development activities of the PXB mouse business are focused on developing applications and establishing intellectual property rights.」

「The research and development activities of the PXB mouse business are focused on developing applications and establishing intellectual property rights.」